市場調査レポート
商品コード
1566904

脂質ナノ粒子市場:タイプ別、用途別、エンドユーザー別:世界の機会分析と産業予測、2024年~2033年

Lipid Nanoparticles Market By Type , By Application By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033


出版日
ページ情報
英文 220 Pages
納期
2~3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
脂質ナノ粒子市場:タイプ別、用途別、エンドユーザー別:世界の機会分析と産業予測、2024年~2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 220 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の脂質ナノ粒子市場は、2023年に9億米ドルと評価され、2024年から2033年にかけて13.1%のCAGRで成長し、2033年には31億米ドルに達すると予測される

脂質ナノ粒子(LNP)は、主に脂質からなる直径10~1000ナノメートルのナノスケール粒子です。医薬品、ワクチン、遺伝物質などの治療薬をカプセル化し、分解から保護し、ドラッグデリバリーや効能を高めるように設計されています。LNPは生体膜の構造を模倣することができるため、生体適合性があり、効率的に細胞と相互作用し、細胞内に浸透することができます。脂質組成には通常、リン脂質、コレステロール、その他の脂質分子が含まれ、ナノ粒子の構造を安定化させ、内包された物質の放出を制御するのに役立っています。

脂質ナノ粒子市場の成長は、がん、糖尿病、心血管疾患、神経障害などの慢性疾患の有病率の上昇と、高度なドラッグデリバリーシステムに対する需要の急増によってもたらされます。これらの疾患は、従来の方法で投与すると深刻な副作用を伴う薬剤による長期的な治療を必要とすることが多いです。LNPは、治療薬を標的かつ持続的に送達することで、全身的な副作用を軽減し、患者のコンプライアンスを向上させるという有望な代替手段を提供します。例えば腫瘍学では、LNPは化学療法剤を腫瘍細胞に直接送達し、健康な組織へのダメージを最小限に抑えるために使用されます。

しかし、LNPベースの製剤の製造と開拓には、ナノ粒子の安定性と有効性を確保するための高度な技術と厳格な品質管理措置が製造工程に含まれるため、それに伴う高コストが製造コストの上昇につながり、市場の成長を制限しています。これとは逆に、ナノテクノロジーの進歩により、安定性が向上し、標的への送達が可能で、放出が制御された脂質ナノ粒子の開発が容易になった。これによりドラッグデリバリーの新たな道が開かれ、より効果的かつ効率的な治療介入が可能になった。例えば、2022年1月、ファイザー社とメッセンジャーRNA(mRNA)ベースの治療薬を可能にする脂質ナノ粒子(LNP)送達システムの開発に注力するAcuitas Therapeutics社は、ファイザー社がワクチンまたは治療薬開発のために最大10の標的についてAcuitas社のLNP技術を非独占的にライセンスするオプションを持つ開発・オプション契約を締結したと発表しました。

セグメント概要

脂質ナノ粒子市場の分析は、タイプ、用途、エンドユーザー、地域に区分されます。タイプによって、市場は固体脂質ナノ粒子、ナノ構造脂質キャリア、その他に分類されます。用途別では、治療用と調査用に二分されます。エンドユーザー別では、製薬・バイオテクノロジー企業、学術・研究機関、その他に分類されます。地域別では、北米、欧州、アジア太平洋、LAMEAで分析されます。

主な調査結果

タイプ別では、固体脂質ナノ粒子セグメントが2023年に最も高い市場シェアを占めました。

用途別では、治療薬セグメントが2023年の市場で最大シェアを占めました。

エンドユーザー別では、製薬・バイオテクノロジー企業が2023年の市場で最大株主となっています。

地域別では、北米が2023年の脂質ナノ粒子市場を独占しました。

競合シナリオ

本レポートはカスタマイズが可能です。

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡張リスト
  • 過去の市場データ
  • 主要プレーヤーの詳細(所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式)

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 脂質ナノ粒子市場:タイプ別

  • 市場概要
  • 固体脂質ナノ粒子
  • ナノ構造脂質キャリア
  • その他

第5章 脂質ナノ粒子市場:用途別

  • 市場概要
  • 治療薬
  • 研究

第6章 脂質ナノ粒子市場:エンドユーザー別

  • 市場概要
  • 製薬企業およびバイオテクノロジー企業
  • 学術・研究機関
  • その他

第7章 脂質ナノ粒子市場:地域別

  • 市場概要
  • 北米
    • 主な市場動向と機会
    • 米国の脂質ナノ粒子市場
    • カナダの脂質ナノ粒子市場
    • メキシコ脂質ナノ粒子市場
  • 欧州
    • 主な市場動向と機会
    • ドイツの脂質ナノ粒子市場
    • フランス脂質ナノ粒子市場
    • 英国の脂質ナノ粒子市場
    • イタリアの脂質ナノ粒子市場
    • スペインの脂質ナノ粒子市場
    • その他欧州の脂質ナノ粒子市場
  • アジア太平洋
    • 主な市場動向と機会
    • 日本の脂質ナノ粒子市場
    • 中国脂質ナノ粒子市場
    • インド脂質ナノ粒子市場
    • オーストラリア脂質ナノ粒子市場
    • 韓国脂質ナノ粒子市場
    • その他アジア太平洋の脂質ナノ粒子市場
  • ラテンアメリカ・中東・アフリカ
    • 主な市場動向と機会
    • ブラジル脂質ナノ粒子市場
    • サウジアラビア脂質ナノ粒子市場
    • 南アフリカの脂質ナノ粒子市場
    • その他のラテンアメリカ・中東・アフリカの脂質ナノ粒子市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング(2023年)

第9章 企業プロファイル

  • ABP Biosciences, LLC.
  • Merck KGaA
  • Cytiva
  • CD Bioparticles
  • CordenPharma
  • Precigenome LLC.
  • Beam Therapeutics
  • Acuitas Therapeutics.
  • Helix Biotech, Inc.
  • Genevant Sciences Corporation
目次
Product Code: A323703

The global lipid nanoparticles market was valued at $0.9 billion in 2023, and is projected to reach $3.1 billion by 2033, growing at a CAGR of 13.1% from 2024 to 2033

Lipid nanoparticles (LNPs) are nanoscale particles ranging from 10 to 1000 nanometers in diameter, primarily composed of lipids. They are designed to encapsulate therapeutic agents such as drugs, vaccines, and genetic materials, protecting them from degradation and enhancing their delivery and efficacy. LNPs can mimic the structure of biological membranes, making them biocompatible and capable of efficiently interacting with and penetrating cells. Their lipid composition typically includes phospholipids, cholesterol, and other lipid molecules that aid in stabilizing the nanoparticle structure and controlling the release of the encapsulated cargo.

The growth of the lipid nanoparticles market is driven by rise in the prevalence of chronic diseases, such as cancer, diabetes, cardiovascular diseases, and neurological disorders, and surge in demand for advanced drug delivery systems. These conditions often require long-term treatment with drugs that have severe side effects when administered through traditional methods. LNPs offer a promising alternative by enabling targeted and sustained delivery of therapeutic agents, thereby reducing systemic side effects and improving patient compliance. In oncology, for instance, LNPs are used to deliver chemotherapeutic agents directly to tumor cells, minimizing damage to healthy tissues.

However, high cost associated with the production and development of LNP-based formulations, as the manufacturing process involves sophisticated technology and stringent quality control measures to ensure the stability and efficacy of the nanoparticles, leads to increased production costs which limit the market growth. On the contrary, advances in nanotechnology facilitated the development of lipid nanoparticles with enhanced stability, targeted delivery, and controlled release properties. This opened new avenues for drug delivery, allowing for more effective and efficient therapeutic interventions. For instance, in January 2022, Pfizer Inc. and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA) -based therapeutics announced that they had entered into a development and option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas' LNP technology for up to 10 targets for vaccine or therapeutic development.

Segmentation Overview

The lipid nanoparticles market analysis is segmented into type, application, end user, and region. Depending on type, the market is categorized into solid lipid nanoparticles, nanostructured lipid carriers, and others. By application, it is bifurcated into therapeutics and research. As per end user, the market is classified into pharmaceutical & biotechnology companies, academic & research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the solid lipid nanoparticles segment held the highest market share in 2023.

Depending on the application, the therapeutics segment accounted for maximum share in the market in 2023.

According to end user, the pharmaceutical & biotechnology companies have been the largest shareholder in the market in 2023.

Region wise, North America dominated the lipid nanoparticles market in 2023.

Competitive Scenario

The major players operating in the lipid nanoparticles market include ABP Biosciences, LLC., Merck KGaA, Cytiva, CD Bioparticles, CordenPharma, Precigenome LLC., Beam Therapeutics, Acuitas Therapeutics, GENEVANT SCIENCES CORPORATION, and Helix Biotech, Inc. Other players in lipid nanoparticles market includes Arbutus Biopharma, and Croda International Plc. These players have adopted several strategies, including mergers & acquisitions, collaborations, product innovation & diversification, and partnerships, to maintain their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Solid Lipid Nanoparticles
  • Nanostructured Lipid Carriers
  • Others

By Application

  • Therapeutics
  • Research

By End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • ABP Biosciences, LLC.
    • Merck KGaA
    • Cytiva
    • CD Bioparticles
    • CordenPharma
    • Precigenome LLC.
    • Beam Therapeutics
    • Acuitas Therapeutics.
    • Helix Biotech, Inc.
    • Genevant Sciences Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: LIPID NANOPARTICLES MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Solid Lipid Nanoparticles
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Nanostructured Lipid Carriers
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Others
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: LIPID NANOPARTICLES MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Therapeutics
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Research
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: LIPID NANOPARTICLES MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Pharmaceutical And Biotechnology Companies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Academic And Research Institutes
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Others
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: LIPID NANOPARTICLES MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Lipid Nanoparticles Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Lipid Nanoparticles Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Lipid Nanoparticles Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Lipid Nanoparticles Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Lipid Nanoparticles Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Lipid Nanoparticles Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Lipid Nanoparticles Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Lipid Nanoparticles Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Lipid Nanoparticles Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Lipid Nanoparticles Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Lipid Nanoparticles Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Lipid Nanoparticles Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. Australia Lipid Nanoparticles Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Lipid Nanoparticles Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Lipid Nanoparticles Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Lipid Nanoparticles Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Lipid Nanoparticles Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Lipid Nanoparticles Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Lipid Nanoparticles Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. ABP Biosciences, LLC.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Merck KGaA
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Cytiva
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. CD Bioparticles
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. CordenPharma
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Precigenome LLC.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Beam Therapeutics
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Acuitas Therapeutics.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Helix Biotech, Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Genevant Sciences Corporation
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments